microcures



microcures

Transformative siRNA Therapeutic Platform for Cellular-Driven Tissue Repair & Regeneration


MicroCures Overview

- **Preclinical drug development company** with growing portfolio of siRNA therapeutics designed to significantly accelerate and improve the quality of tissue/nerve/organ repair and regeneration
- Currently focused on advancing programs to the clinic in 3 high impact corneal, nerve, and dermal indications

Novel Science

- Dynamically harnesses microtubules as a therapeutic target
- Discovery of untapped core cellular regulatory mechanisms in two target families: accelerator portfolio and decelerator portfolio
- Accelerator technology combines siRNA with novel FL2 target
- Proven in vivo efficacy and extensive functionality data for all 3 lead indications (please see reverse for data study summaries)

Progressive Development Pipeline



Robust IP Portfolio

- Extensive patent portfolio both worldwide license from Albert Einstein College of Medicine & Internally Developed
- 13 issued & 37 pending composition, method, formulation
- · Patent lives extend to 2041

Partnership Opportunities

- Capital efficient business model focused on achieving nearterm directionality/milestones AND creating longer term value optionality for MicroCures and our partners
- Currently seeking additional capital and licensing partner(s)
 to further accelerate 2+ programs to the clinic, continue to
 expand IP portfolio, and build out leadership execution team

at a glance

- Leader in the science of cell movement and its integral role in tissue repair/regeneration and disease progression
- Novel and validated MOA for predictably and transiently controlling innate cell movement
- Locally administered, non-systemic siRNA formulations consistently demonstrate faster and more complete healing & regeneration of multiple tissue types – with significant advantages versus current standards of care and systemic treatments
- Diverse pipeline of programs focused on both orphan pathways and large unmet need populations -positioned to advance rapidly to clinical trials
- Robust patent portfolio provides both broad product/ platform protection and highvalue licensing or co-development opportunities
- Capital efficient business development to-date, with substantial non-dilutive funding from multiple government agencies and collaborations

For non-confidential presentation and additional information please contact us at info@microcures.com



microcures



MicroCures Platform Summary

LEAD CANDIDATES FOR CLINIC

Accelerator Technology

- Corneal wound repair (NK+)
- Neural regeneration: PNS & CNS
- Dermal wound & burn repair
- Cardiac tissue repair
- → Pulmonary fibrosis prevention
- Solid tumor cell therapy penetration

Additional potential Accelerator applications include: neurodegenerative disease/trauma repair; hair follicle regrowth

CONTROLLING CELL MIGRATION

(Local/Topical

- √ Local/Topical
- √ Non-Systemic
- ✓ Transient
- ✓ Cells Retain
 Their Identity

Decelerator Technology

- Inhibit fibrosis
- Anti-metastasis
- → Block tumor angiogenesis

3 Leading Programs:

Neurotrophic Keratitis Treatment

- Orphan degenerative disease -- damage of trigeminal innervation
- MCR-231 eye drop accelerates regeneration of trigeminal neurons and repair of the cornea – MULTIPLE therapeutic outcomes
- > 2-fold increase in rate and quality of corneal healing
- Potential label expansion into dry eye (>16M US patients), diabetic keratopathy (~225M global patients), post-Lasik surgery complications


Prednisone siControl MCR-231

Cavernous Nerve Regeneration after Radical Prostatectomy

- Cavernous nerves (CN) run along the prostate to the corporal tissue and control erectile function -- they are often damaged during radical prostatectomy (RP) leading to erectile dysfunction (ED)
- Nearly all patients experience some form of ED post-RP due to CN damage -- for many, ED persists > 5 years post-surgery
- MCR-420, a biodegradable hydrogel, can be applied to the nerves during surgery -- in preclinical studies, MCR-420 accelerated cavernous nerve regeneration post severing, leading to significantly faster and more complete restoration of erectile function.

Uninjured





Electron micrographs of cross sections of transected and MCR-420 treated nerves show regenerated axons distal to transection site, comparable to uninjured nerves

Burn/Excision Wound Repair

- >600,000 burn wounds are treated in the clinic annually in the United States alone; patients are at risk of infection without proper re-epithelialization of these wound(s).
- MCR-111 is topically applied to improve healing. Preclinical studies in rodent and pig demonstrate a greater than 2x improvement in the rate of wound closure after treatment.
- MCR-111 treated wounds exhibit **improved quality of restored skin**, with the emergence of mature dermal collagen, hair follicles, nerves and sweat glands and significantly less scarring.

Vehicle/Wash siControl











MCR-111

This fact sheet contains statements about MicroCures' expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to various factors. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so.